Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes

Authors: Stephanie Edwards, Xuanyao He, Wenjie Wang, Jiat-Ling Poon, Eric Meadows, David Price, Jennal Johnson, Howard Wolpert, William Polonsky

Abstract

Objective: This study used connected pen to determine missed bolus dose (MBD) frequency during masked and unmasked continuous glucose monitoring (CGM) periods and examined its link with time-in-range (TIR), time-above-range (TAR), time-below-range (TBR), and key participant characteristics in people with diabetes. Methods: This was a 12-week, single-arm, exploratory, two-period study for people with type 1 diabetes (T1D) or type 2 diabetes (T2D). The primary objective was to estimate the average number of MBD during masked and real-time CGM use. The secondary objective was to estimate the average percent TIR and its relationship to MBD. An exploratory objective was to investigate the participant characteristics that were associated with MBD. Data were analyzed for differences in MBD by diabetes type and other participant characteristics, by CGM period, and by hypoglycemic fear scores. Results: Participants (n = 64; T1D, n = 38; T2D, n = 26) were 48 ± 11.9 years old and 44% were female. From the masked to the unmasked period, MBD, %TAR, %TBR, and glycated hemoglobin decreased significantly (0.74 MBD/day to 0.62 MBD/day, P = 0.008; 53.6%-48.1%, P = 0.004; 4.49%-2.93%, P < 0.001; mean 8.8%-8.4%, P < 0.001, respectively), while %TIR increased significantly (41.9%-49.0%, P < 0.001). MBD/day was negatively associated with TIR (P = 0.016) and positively associated with TAR (P = 0.015) for T1D and positively associated with TBR (P = 0.024) for T2D in the masked period only. MBD was significantly associated with fear of hypoglycemia for T2D, but not T1D. Conclusions: MBD is associated with reduced TIR when CGM is masked and tailored therapeutic approaches are needed for T1D and T2D populations.

Source: https://pubmed.ncbi.nlm.nih.gov/34524010/

Share the Post:

BDI Monthly Events

May 7OMEGA Conference
May 7: As a keynote speaker at OMEGA, the First International Conference on Once-Weekly Glycated Albumin Monitoring for Diabetes, Dr. Polonsky (BDI President) will be presenting on “Glucose Monitoring and Behavior Change” (Tokyo, Japan).
May 14Case Consultation
May 14: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at [email protected] if you are in the greater San Diego area and would like further information about this program.
May 18T1D Meet Up
May 18: Time for another T1D meet-up! Our friends and colleagues at GrownupT1Ds, a wonderful nonprofit here in southern California, is organizing another fun social event for adults with type 1 diabetes. This time it is a Walk, Talk & Picnic, and it begins at 11 am at the Bommer Canyon Trail (1 Sunnyhill, Irvine, CA). 92084. This event is free, but please RSVP Kelly Daes at www.grownupt1ds.org.
May 23SITEC 2025
May 23: Dr. Polonsky will be presenting (virtually) on “Far Beyond Time in Range: Exploring the Promises and Limitations of CGM” at SITEC 2025, Innovation and Technology Transforming Diabetes Care (Sao Paolo, Brazil). https://sitec.diabetes.org.br/